Skip to content
Home/Companies/Biotech/Xintela

Xintela

Biotech·Sweden·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Xintela?

Xintela is a Swedish Biotech company, currently owned by Flerie since 2022.

Hand-verified · updated 2026-08-17

Open JSON · CC-BY
Flerie
Investor
Flerie
Flerie Invest · 2011 · Life Sciences VC

Key facts

HQSweden
SectorBiotech
StatusActive

More from Flerie Invest

Other portfolio companies in the same fund.

Frontier Biosolutions
Active
PharmaGermany· 2023
Mendus
Active
BiotechSweden· 2023
A3P Biomedical
Exited 2025
BiotechSweden· 2022
Alder Therapeutics
Active
BiotechSweden· 2022
AnaCardio
Active
BiotechSweden· 2022
Bohus Biotech
Active
PharmaSweden· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Xintela?

Xintela is currently owned by Flerie, through Flerie Invest, since 2022.

When did Flerie acquire Xintela?

Flerie acquired Xintela in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue